Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects

Yoshihiro Kamada a,b, Ryota Hashimoto c,d, Hidenaga Yamamori d, Yuka Yasuda d, Tetsuo Takehara b, Yuko Fujita c, Kenji Hashimoto e, Eiji Miyoshi a,b

a Department of Molecular Biochemistry & Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
b Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
c Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Suita, Osaka 565-0871, Japan
d Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
e Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Chiba 260-8670, Japan

A R T I C L E   I N F O

Article history:
Received 12 January 2016
Received in revised form 17 February 2016
Accepted 19 February 2016
Available online 23 February 2016

Keywords:
Aspartate aminotransferase
Alanine aminotransferase
Glutamate
Memory function

A B S T R A C T

Background & aims: Blood aspartate aminotransferase (AST) and alanine transaminase (ALT) levels are the most frequently reliable biomarkers of liver injury. Although AST and ALT play central roles in glutamate production as transaminases, peripheral blood levels of AST and ALT have been regarded only as liver injury biomarkers. Glutamate is a principal excitatory neurotransmitter, which affects memory functions in the brain. In this study, we investigated the impact of blood transaminase levels on blood glutamate concentration and memory.

Methods: Psychiatically, medically, and neurologically healthy subjects (n = 514, female/male: 268/246) were enrolled in this study through local advertisements. Plasma amino acids (glutamate, glutamine, glycine, N-serine, and t-serine) were measured using a high performance liquid chromatography system. The five indices, verbal memory, visual memory, general memory, attention/concentration, and delayed recall of the Wechsler Memory Scale-Revised were used to measure memory functions.

Results: Both plasma AST and ALT had a significant positive correlation with plasma glutamate levels. Plasma AST and ALT levels were significantly negatively correlated with four of five memory functions, and plasma glutamate was significantly negatively correlated with three of five memory functions. Multivariate analyses demonstrated that plasma AST, ALT, and glutamate levels were significantly correlated with memory functions even after adjustment for gender and education.

Conclusions: As far as we know, this is the first report which could demonstrate the impact of blood transaminase levels on blood glutamate concentration and memory functions in human. These findings are important for the interpretation of obesity-induced metabolic syndrome with elevated transaminases and cognitive dysfunction.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Peripheral blood levels of aspartate aminotransferase [AST/GOT (glutamate-oxalacetate transaminase)] and alanine transaminase [ALT/GPT (glutamate-pyruvate transaminase)] have been regarded simply as liver injury biomarkers [1,2]. In various etiologies from viral hepatitis to nonalcoholic fatty liver disease (NAFLD), blood AST and ALT levels are elevated and are frequently reliable biomarkers of hepatotoxic effects. However, AST and ALT also play central roles in amino acid metabolism as transaminases [1,2]. Specifically, AST and ALT catalyze transamination from aspartate or alanine to glutamate and are important positive regulators of tissue glutamate levels [1,3]. In addition, a previous report demonstrated that transaminases in human blood have efficient enzymatic transamination activity [4]. However, there are no reports that have demonstrated the correlation between blood transaminases and glutamate levels in human subjects.

Glutamate plays pivotal roles in many physiological brain functions including memory [5,6]. Glutamate is a principal excitatory neurotransmitter of the central nervous system [7]. Memory dysfunction can affect our cognitive function, and peripheral blood glutamate levels have been reported to be altered in many cognitive function disorders, such as...
Asperger’s syndrome [8] and schizophrenia [9]. The glutamate concentration in the blood is thought to have effects on brain function despite the existence of the blood brain barrier (BBB). Indeed, peripheral blood glutamate levels positively correlate with the concentration of glutamate in cerebrospinal fluid (CSF) [10,11]. In rodent models, systemic administration of monosodium glutamate (MSG) induces BBB breakdown through its hypertonic effect [12]. There have been many reports that have demonstrated that glutamate and glutamatergic receptor have significant effects on memory functions [13,14]. One of the mechanisms by which glutamate affects memory function is through glutamatergic induction of long term potentiation (LTP) of synaptic strength thorough activation of the glutamate receptors [13,14].

In consideration of these findings, we hypothesized that blood transaminase levels could change the blood glutamate concentration and would have significant effects on cognitive functions in humans. To confirm our hypothesis, we investigated the relationship between blood transaminase (AST and ALT) levels, brain function-related amino acid levels [glutamate, glutamine, glycine, D-serine, and L-serine], and memory functions (verbal memory, visual memory, general memory, attention/concentration, and delayed recall) in 514 healthy subjects without any psychological diseases or current medication.

2. Materials and methods

2.1. Ethical committee approval

The protocol and informed consent document were approved by the institutional review boards at Osaka University Graduate School of Medicine and Chiba University (No. 592). Written informed consent was obtained from all subjects and the study was conducted in accordance with the Helsinki Declaration.

2.2. Memory function assessment and laboratory measurements

A full version of the WMS-R [16,17], a measure that is generally used to measure memory, was administered to the subjects, as previously described [18]. The five indices, verbal memory, visual memory, general memory, attention/concentration, and delayed recall of the WMS-R were used in the analysis. The scores of indices were corrected by age. Memory functions were positively correlated with the scores of indices. The mean value of these scores was set to 100, and one standard deviation (S.D.) was defined as 15. Blood biochemical variables [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] were measured with a conventional automated analyzer (Mitsubishi MEDIENCE, Kobe, Japan).

2.3. Determination of plasma amino acid levels

Measurement of plasma D-serine and L-serine were carried out using a column-switching high performance liquid chromatography (HPLC) system (Shimadzu Corporation, Kyoto, Japan) [19,20]. Measurement of plasma glutamine, glutamate, and glycine was carried out using an aminotransferase (AST) and alanine aminotransferase (ALT) were measured with a conventional automated analyzer (Mitsubishi MEDIENCE, Kobe, Japan).

2.4. Study subjects

A total of 514 healthy volunteers were enrolled in this study, as previously described [22,23]. The study subjects were recruited through local advertisements. Psychiatrically, medically, and neurologically healthy subjects were evaluated using the structured clinical interview for DSM-IV (SCID), non-patient version. Subjects were excluded if they had neurological or medical conditions that could potentially affect the central nervous system, such as atypical headache, head trauma with loss of consciousness, chronic lung disease, kidney disease, chronic thyroid disease, active stage cancer, cerebrovascular disease, epilepsy, or seizures. The criteria for exclusion from this study also included a history of known hepatic diseases and virus hepatitis marker positive subjects (HCV-antibody and HBs antigens). The detailed information regarding the subjects is shown in Table 1. Briefly, the gender ratio was 268/246 (female/male), mean age was 31.8 ± 12.3 years old, and mean education length was 15.0 ± 1.8 years.

2.5. Statistical analysis

Statistical analysis was conducted using JMP Pro 11.0 (SAS Institute Inc., Cary, NC) and SPSS 20.0 (SPSS Japan Inc., Tokyo, Japan) software. Variables were expressed as mean ± S.D. As AST, ALT, glutamate, glycine, D-serine, and L-serine did not show a Gaussian distribution, these parameters were common log-transformed before analysis. The Wilcoxon test and Spearman R correlations were used for the statistical analyses in this study. Multivariate logistic regression analyses were conducted to identify parameters that significantly contribute to each memory function. Differences were considered statistically significant at P < 0.05.

3. Results

3.1. Plasma transaminase (AST and ALT) levels significantly correlate with the plasma glutamate level

AST and ALT are transaminases which catalyze transamination from aspartate or alanine to glutamate. However, as far as we know, there are no reports that have investigated the relationship between blood transaminase and glutamate levels. First, we investigated the correlation between plasma transaminase levels and glutamate levels in our subjects. As expected, we found a significant and positive correlation between transaminases (AST and ALT) and glutamate (AST: R = 0.19, P = 1.1 × 10^{-5}; ALT: R = 0.30, P = 5.0 × 10^{-12}) (Fig. 1, Table 2). Both plasma AST and ALT levels had significant negative correlations with plasma glycine and L-serine [AST: R = −0.22, P = 7.5 × 10^{-7} (D-serine), ALT: R = 0.22, P = 1.1 × 10^{-5}; ALT: R = 0.30, P = 5.0 × 10^{-12}] (Fig. 1, Table 2). Both plasma AST and ALT levels had significant negative correlations with plasma glycine and L-serine [(AST: R = −0.12, P = 7.2 × 10^{-3} (glycine), R = 0.22, P = 7.5 × 10^{-7} (l-serine); ALT: R = 0.19, P = 3.5 × 10^{-4} (glycine), R = 0.22, P = 6.5 × 10^{-8} (l-serine)]. There were no significant correlations between plasma transaminases and other amino acids [(AST: R = −0.043, P = 0.34 (glutamine), R = 0.074, P = 0.095 (l-serine); ALT: R = −5.3 × 10^{-5}, P = 0.91 (glutamine), R = 0.013, P = 0.77 (l-serine)]. A previous report has demonstrated that blood transaminases have enzymatic transamination activity [4]. Our results indicate that the blood transaminase concentration defines the concentration of peripheral blood glutamate in human subjects.

Table 1

| Number | 514 |
|--------|-----|
| Age (years) | 31.8 ± 12.3 |
| Gender (F/M) | 268/246 |
| Education (years) | 15.0 ± 1.8 |
| AST (U/L) | 19.1 ± 6.6 |
| ALT (U/L) | 17.3 ± 12.9 |
| Gln (μM) | 528.4 ± 72.7 |
| Gly (μM) | 223.0 ± 54.8 |
| Glu (μM) | 32.9 ± 16.4 |
| D-Serine (μM) | 0.95 ± 0.32 |
| L-Serine (μM) | 119.7 ± 27.4 |
| Verbal memory | 112.9 ± 13.7 |
| Visual memory | 105.0 ± 9.6 |
| General memory | 112.4 ± 13.0 |
| Attention/concentration | 110.1 ± 12.7 |
| Delayed recall | 110.0 ± 12.2 |

Data are presented as the mean ± standard deviation (S.D.).

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; Gln, glutamine; Gly, glycine; Glu, glutamate.
3.2. The correlation among plasma transaminase levels, amino acid levels, and memory functions

Next, we investigated the relationships between plasma transaminase levels and memory functions (Table 3). Both plasma AST and ALT levels were significantly and negatively correlated with four of five memory functions [verbal memory: R = −0.11, P = 0.014 (AST), R = −0.13, P = 4.0 × 10⁻³ (ALT); visual memory: R = −0.11, P = 0.012 (AST), R = −0.11, P = 0.014 (ALT); general memory: R = −0.13, P = 0.0044 (AST), R = −0.14, P = 0.0013 (ALT); and delayed recall: R = −0.13, P = 0.0033 (AST), R = −0.15, P = 4.0 × 10⁻⁴ (ALT)] (Fig. 2A, B, C, E), but were not correlated with attention/concentration (R = −0.022, P = 0.61) (Fig. 2D). Plasma glutamate levels demonstrated a similar correlation as transaminases with memory functions (Table 3). Other amino acids (glutamine, glycine, d-serine, and l-serine) did not correlate with verbal, visual, or general memory or delayed recall.

As shown above, plasma AST, ALT, and glutamate levels were significantly correlated with verbal, visual, and general memory and delayed recall. To exclude the effects of gender differences and level of education, we conducted multivariate analyses for each memory function adjusted for gender and years of education (Table 4A, B, C). Plasma AST level was a significant determinant for verbal, visual, and general memory and delayed recall. Plasma ALT level was a significant determinant of verbal and general memory and delayed recall. Plasma glutamate level was a significant determinant of verbal, general memory, and delayed recall. These results indicate that plasma AST, ALT, and glutamate levels are significantly correlated with memory functions even after adjustment for gender and education length.

4. Discussion

In the present study, we demonstrated the correlations among plasma transaminase levels, amino acid levels, and memory functions. As far as we know, our study is the first report to demonstrate that plasma AST and ALT have significant positive correlations with peripheral blood glutamate concentrations and significant negative correlations with memory functions in healthy subjects. In addition, we found that plasma glutamate levels also have significant and negative relationships with memory functions. Our findings indicate that plasma transaminase levels have significant impact on memory functions through changes in plasma glutamate concentration.

AST and ALT have been known to have critical roles in glutamate production [1,3,4]. Glutamate is known to be the major excitatory neurotransmitter of the central nervous system [7] and plays many important roles in brain functions. Plasma glutamate levels positively correlate with the CSF glutamate concentration [10,11]. In male patients with schizophrenia, plasma levels of glutamate are elevated compared with those in control subjects [9]. A meta-analysis has also demonstrated that peripheral glutamate levels in schizophrenia patients are significantly higher than in controls [24]. In addition, significant correlations have been reported in various cognitive disorder diseases between brain glutamate levels and disease symptoms [13]. Therefore, although we did not measure CSF glutamate levels, increased plasma glutamate levels would have significant effects on brain functions. On the contrary, there have been some reports that have demonstrated no significant relationships between blood glutamate levels and cognitive functions in schizophrenia patients [25–27]. Drugs used in these patients would not have any effects on serum glutamate concentration and cognitive functions, and the relationships would be diminished in these patients. In our study, we have demonstrated significantly positive relationships between peripheral blood glutamate and these transaminases. We also found that both plasma transaminases and glutamate levels in healthy subjects were negatively correlated with memory functions. These findings indicate that elevation of plasma transaminase levels induces memory dysfunction through plasma glutamate level elevation in healthy subjects under no medication.

Recent studies have demonstrated that brain dysfunction induces food addiction and obesity [28,29]. Binge eating disorder is characterized by a compulsive engagement in excessive food consumption which results in obesity [30]. In particular, glutamate and glutamate receptors have been found to play a role in the regulation of food intake and modification of binge eating (known as the “glutamate hypothesis”) [31–33]. MSG administration in rodent models is often used to induce overeating and obesity [34,35]. In humans, glutamate N-methyl-D-aspartate (NMDA) receptor agonist suppresses food intake, and the NMDA receptor antagonist, acamprosate, has been found to decrease food dependency and weight gain [32,36–38]. These findings indicate that glutamatergic system regulation may be useful for the treatment of eating disorders and obesity. In the DSM-4 (Diagnostic and Statistical...
Manual of Mental Disorders, Forth Edition), substance addiction is defined as a cluster of cognitive, behavioral, and psychological symptoms associated with the continuous use of a substance despite significant problems caused by the substance [39]. While obesity is characterized by overeating and the inability to stop overeating despite the desire to do so, these symptoms are remarkably parallel to those described in the DSM-4 for substance addiction. Therefore, some forms of obesity should be included as a mental disorder driven by a food addiction [40]. Obesity is not only closely associated with fatty liver disease, but also induces cognitive dysfunction [41–43]. Considered together, transaminase elevation in obesity-related fatty liver patients may trigger cognitive dysfunction and food addiction and might induce further weight gain.

Other amino acids, such as glutamine, glycine, d-serine, and l-serine, also have significant effects on brain functions [21,44,45]. Among these amino acids, d-serine and glycine are known as co-agonists of the NMDA receptor, and facilitate excitatory glutamatergic neurotransmission at synapses within the nervous systems [46–48]. Because phencyclidine, a non-competitive antagonist of the NMDA receptor, induces schizophrenia-like symptoms in healthy subjects, recent research on schizophrenia has focused on hypofunction of the NMDA receptor. However, no significant correlations have been cited between these amino acids (glycine and d-serine) and memory functions in our study subjects.

Obesity is a central and causal component of metabolic syndrome (Mets) and is almost always induced by overeating resulting from

Fig. 2. Relationships between plasma transaminase level and memory functions. (A) Relationship between plasma transaminase level and verbal memory. (B) Relationship between plasma transaminase level and visual memory. (C) Relationship between plasma transaminase level and general memory. (D) Relationship between plasma transaminase level and attention/concentration. (E) Relationship between plasma transaminase level and delayed recall.
food addiction [29,49]. Mets, a cluster of obesity-related diseases including NAFLD, is a critical growing medical problem in industrialized countries of the world. NAFLD is among the most common causes of chronic liver disease in obese people [41]. NAFLD patients have food dependency [50], and weight reduction is useful for the prevention of NAFLD progression [51,52]. However, clinical hepatologists often encounter NAFLD patients who do not stop overeating in spite of frequent nutritional guidance [50]. In the rodent fatty liver model, it has been reported that memory performance is impaired and exenatide (glucagon-like peptide-1 analog) treatment improves memory performance [53]. In addition, 85% of NAFLD patients have mild or moderate cognitive dysfunction [54]. We suppose a number of the subjects in the present study with elevated transaminase levels would have NAFLD. In NAFLD patients, cognitive dysfunction induced by transaminase elevation has some effect on their food dependency. A cross-sectional and longitudinal study is needed to elucidate the relationships among blood transaminase levels, glutamate levels, and memory functions in NAFLD patients.

Our study has some limitations. First, our study is a cross-sectional study. The effects of a plasma transaminase level change on plasma glutamate levels and memory functions were not elucidated. Longitudinal studies are needed to investigate this issue in more detail. Second, our study lacks the inclusion of factors related to Mets, such as body weight, blood sugar, and lipid levels. Therefore, the effects of factors other than transaminase and glutamate levels on memory functions were not assessed in our study. However, our study has a strong advantage in terms of the large number of healthy subjects (n = 514) included. Our healthy subjects were under no medication and did not have any past history of psychiatric diseases with memory dysfunction. Therefore, we believe a meaningful

|                   | Glu  | Gln  | Gly  | D-Serine | L-Serine |
|-------------------|------|------|------|----------|----------|
|                   | R    | P value | R    | P value | R    | P value | R    | P value | R    | P value |
| Verbal memory     | −0.12 | 8.6 × 10^{-3} | −0.031 | 0.48 | −0.018 | 0.69 | 0.05 | 0.25 | −0.006 | 0.90 |
| Visual memory     | −0.084 | 0.056 | −0.058 | 0.19 | −7.0 × 10^{-4} | 0.99 | 0.046 | 0.30 | 0.024 | 0.59 |
| General memory    | −0.13 | 3.4 × 10^{-3} | −0.038 | 0.39 | −0.011 | 0.80 | 0.059 | 0.18 | −0.006 | 0.90 |
| Attention/concentration | 0.043 | 0.33 | 0.088 | 0.046 | −0.031 | 0.49 | 0.046 | 0.28 | −0.098 | 0.027 |
| Delayed recall    | −0.12 | 7.8 × 10^{-3} | −0.0096 | 0.83 | −9.0 × 10^{-3} | 0.84 | 0.052 | 0.037 | −0.003 | 0.95 |
assessment of plasma transaminases, amino acids, and memory functions were performed in the present study. In conclusion, we demonstrate the significant relationships among plasma transaminases (AST and ALT), plasma glutamate levels, and memory functions in 514 healthy subjects. Considering our findings, we hypothesize that plasma transaminase elevation in obesity-induced fatty liver patients evokes memory function disorders and leads to food dependency, which results in further obesity (vicious liver-brain cycle). Breaking up this vicious cycle should ameliorate metabolic syndrome progression.

Acknowledgments

A part of this work carried out care of support from Brain/MINDS and Comprehensive Research on Disability Health and Welfare by AMED, Kakenhi [25293250-Grant-in-Aid for Scientific Research (B), 15H04810-Grant-in-Aid for Scientific Research (B), 23659565-Grant-in-Aid for Challenging Exploratory Research], and Grant-in-Aid for Scientific Research on Innovative Areas (Comprehensive Brain Science Network) by MEXT. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Table 4

| Factors                  | ES (gender, education, AST) | Estimated value | S.E. | t value | P value |
|--------------------------|-----------------------------|-----------------|------|---------|---------|
| (A) Model 1 (gender, education, AST) | Gender (male) | 0.51           | 0.87 | 0.38    |         |
|                          | Education (years) | 0.09           | 0.32 | 2.15    | 0.032   |
|                          | AST (U/L) | 0.023           | 0.092 | 2.5    | 0.013   |
| (B) Model 2 (gender, education, ALT) | Gender (male) | -0.23          | 0.64 | -0.36   | 0.72    |
|                          | Education (years) | 0.82           | 0.34 | 2.43    | 0.016   |
| (C) Model 3 (gender, education, glutamate) | Gender (male) | 0.098          | 0.24 | 0.26    | 0.77    |
|                          | Education (years) | 0.053          | 0.082 | 2.8    | 5.3 × 10^-3 |

Abbreviations: S.E. standard error.

References

[1] J. Ozer, M. Ratzer, M. Shaw, W. Bailey, S. Schomaker, The current state of serum biomarkers of hepatotoxicology, Toxicology 245 (2008) 194–205.
[2] S. Sookloin, C.J. Pirola, Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine, World J. Gastroenterol. 21 (2015) 711–725.
[3] F.A. Gallagher, M.J. Kettunen, S.E. Day, D.E. Hu, M. Karlsson, A. Cisselsson, M.H. Lerche, K.M. Brindle, Detection of tumor glutamate metabolism in vivo using (13)C magnetic resonance spectroscopy and hyperpolarized [(13)C]glutamate, Mag. Reson. Med. 66 (2011) 112–119.
[4] J.S. Ladue, F. Wroblewski, A. Karmen, Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction, Science 120 (1954) 497–499.
[5] H.J. Reis, C. Guatimosim, M. Paquet, M. Santos, F.M. Ribeiro, A. Kummer, G. Scheithauer, J.V. Salgado, L.B. Vieira, A.L. Teixeira, A. Palotas, Neuro-transmitters in the central nervous system & their implication in learning and memory processes, Curr. Med. Chem. 16 (2009) 796–840.
[6] F.W. Kalivas, The glutamate homeostasis hypothesis of addiction, Nat. Rev. Neurosci. 10 (2009) 561–572.
[7] J. Coyle, M. Leski, J. Morrison, in: K. Davis, D. Charney, J. Coyle (Eds.), The Diverse Roles of γ-Glutamic Acid in Brain Signal Transduction 2002, pp. 71–90.
[8] S. Aldred, B.S. Glaeser, W. Millington, R.J. Wurtman, Monosodium glutamate neurotoxicity, hyperomolality, and blood-brain barrier dysfunction, Neurobeha. Toxicol. 1 (1979) 279–283.
[9] K. Murrin, P. McGuire, A. Egerton, Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis, Front. Psychiatry 4 (2013) 151.
[10] A. Egerton, S. Brugger, M. Raffin, G.J. Barker, D.I. Lyngbye, P.K. McGuire, J.M. Stone, Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia, Neuropsychopharmacology 37 (2012) 2515–2521.
[11] J. Lisman, R. Saghavachiri, Mechanisms of CaMKII action in long-term potentiation, Nat. Rev. Neurosci. 13 (2012) 169–182.
[12] M. Sugisata, Japanese Wechsler Memory Scale-Revised, Nihonbunkakagakusha, Tokyo (1988) 689–697.
[13] D. Wechsler, Wechsler Memory Scale Revised, revised, Psychological Corporation, 1987 (Place Published).
[14] K. Ohi, R. Hashimoto, Y. Yasuda, M. Fukumoto, K. Nemoto, T. Ohnishi, H. Yamamori, R. Hashimoto, Y. Fujita, S. Numata, Y. Yasuda, M. Fujimoto, K. Ohi, S. Umeda-Yano, A. Higuchi, Y. Hibi, Y. Matsuura, R. Hashimoto, M. Takeda, O. Imura, Methamphetamine and Comprehensive Research on Disability Health and Welfare by AMED, Kakenhi [25293250-Grant-in-Aid for Scientific Research (B), 15H04810-Grant-in-Aid for Scientific Research (B), 23659565-Grant-in-Aid for Challenging Exploratory Research], and Grant-in-Aid for Scientific Research on Innovative Areas (Comprehensive Brain Science Network) by MEXT. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Transparency Document

The Transparency Document associated with this article can be found, in the online version.
tyrosine hydroxylase gene affects IQ in schizophrenia, Psychiatry Clin. Neurosci. 68 (2014) 456–462.

[24] J. Song, A. Viggiano, M. Monda, V. De Luca, Peripheral glutamate levels in schizophrenia: evidence from a meta-analysis, Neuropsychobiology 70 (2014) 133–141.

[25] C.A. Altamura, M.C. Maurice, A. Ferrara, A.R. Moro, G. D’Andrea, F. Zamberlan, Plasma and platelet excitatory amino acids in psychiatric disorders, Am. J. Psychiatry 150 (1993) 1731–1733.

[26] J.S. Kim, H.H. Kornhuber, B. Holzmuller, W. Schmid-Burgk, T. Mergner, G. Kzerpinskii, Reduction of cerebrospinal fluid glutamic acid in Huntington’s chorea and in schizophrenic patients, Arch. Psychiatr. Nervenkr. 228 (1980) (1970): 7–10.

[27] T. Ohnuma, Y. Sakai, H. Maeshima, M. Higa, R. Hanzawa, M. Kitazawa, Y. Hotta, N. Katsuta, Y. Takebayashi, N. Shibata, H. Arai, No correlation between plasma NM2A-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia, Int. J. Psychiatry Med. 44 (2012) 17–27.

[28] A.N. Gearhardt, W.R. Corbin, The role of food addiction in clinical research, Curr. Pharm. Des. 17 (2011) 1140–1142.

[29] F.M. Filbey, U.S. Myers, S. Dewitt, Reward circuit function in high BMI individuals with compulsive overeating: similarities with addiction, NeuroImage 63 (2012) 1800–1806.

[30] A. American Psychiatric Association, A.P. Association, Diagnostic and Statistical Manual of Mental Disorders, 1980.

[31] A.L. Tata, D.R. Kockler, Topiramate for binge-eating disorder associated with obesity, Ann. Pharmacother. 40 (2006) 1993–1997.

[32] S.L. McElroy, A.J. Guerdjikova, E.L. Winstanley, A.M. O’Melia, N. Mori, J. McCoy, P.E. Keck Jr., J.J. Hudson, Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial, Int. J. Eat. Disord. 44 (2011) 81–90.

[33] C.S. Maldonado-Irizarry, C.J. Swanson, A.E. Kelley, Glutamate receptors in the nucleus accumbens shell control feeding behavior via the lateral hypothalamus, J. Neurosci. 15 (1995) 6779–6788.

[34] R. Matyukova, L. Maletinska, J. Maixnerova, Z. Pirnik, A. Kiss, B. Zelezna, Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice, Physiol. Res. 57 (1998) 837–840.

[35] G. Gadino-Cabrera, M.E. Urena-Guerro, M.C. Rivera-Cervantes, A.J. Feria-Velasco, C. Bear-Zarate, Excitotoxicity triggered by neonatal monosodium glutamate treatment and blood–brain barrier function, Arch. Med. Res. 45 (2014) 653–659.

[36] D.B. Guard, T.D. Swartz, R.C. Ritter, G.A. Burns, M. Covasa, NM2A NR2 receptors participate in CCK-induced reduction of food intake and hindbrain neuronal activation, Brain Res. 1266 (2009) 37–44.

[37] J.M. Reich, B. Maunze, K.A. Phillips, S. Choi, Inhibition of food intake by PACAP in the hypothalamic ventromedial nucleus is mediated by NM2A receptors, Physiol. Behav. 133 (2014) 230–235.

[38] S.L. McElroy, A.J. Guerdjikova, N. Mori, A.M. O’Melia, Pharmacological management of binge eating disorder: current and emerging treatment options, Ther. Clin. Risk Manag. 8 (2012) 219–241.

[39] A.P. Association, A.P. Association, Diagnostic and statistical manual of mental disorders (DSM), American psychiatric association, Washington, DC, 1994 143–147.

[40] N.D. Volkow, C.P. O’Brien, Issues for DSM-V: should obesity be included as a brain disorder? Am. J. Psychiatry 164 (2007) 708–710.

[41] E.S. Ford, W.H. Giles, W.H. Dietz, Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition examination survey, JAMA 287 (2002) 356–359.

[42] B. Zelezna, A. Kiss, B. Matyukova, L. Maletinska, J. Maixnerova, Z. Pirnik, A. Kiss, B. Zelezna, Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice, Physiol. Res. 57 (1998) 837–840.

[43] J. Song, A. Viggiano, M. Monda, V. De Luca, Peripheral glutamate levels in schizophrenia: evidence from a meta-analysis, Neuropsychobiology 70 (2014) 133–141.

[44] C.A. Altamura, M.C. Maurice, A. Ferrara, A.R. Moro, G. D’Andrea, F. Zamberlan, Plasma and platelet excitatory amino acids in psychiatric disorders, Am. J. Psychiatry 150 (1993) 1731–1733.

[45] J.S. Kim, H.H. Kornhuber, B. Holzmuller, W. Schmid-Burgk, T. Mergner, G. Kzerpinskii, Reduction of cerebrospinal fluid glutamic acid in Huntington’s chorea and in schizophrenic patients, Arch. Psychiatr. Nervenkr. 228 (1980) (1970): 7–10.

[46] T. Ohnuma, Y. Sakai, H. Maeshima, M. Higa, R. Hanzawa, M. Kitazawa, Y. Hotta, N. Katsuta, Y. Takebayashi, N. Shibata, H. Arai, No correlation between plasma NM2A-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia, Int. J. Psychiatry Med. 44 (2012) 17–27.

[47] A.N. Gearhardt, W.R. Corbin, The role of food addiction in clinical research, Curr. Pharm. Des. 17 (2011) 1140–1142.

[48] F.M. Filbey, U.S. Myers, S. Dewitt, Reward circuit function in high BMI individuals with compulsive overeating: similarities with addiction, NeuroImage 63 (2012) 1800–1806.

[49] A. American Psychiatric Association, A.P. Association, Diagnostic and Statistical Manual of Mental Disorders, 1980.

[50] A.L. Tata, D.R. Kockler, Topiramate for binge-eating disorder associated with obesity, Ann. Pharmacother. 40 (2006) 1993–1997.

[51] S.L. McElroy, A.J. Guerdjikova, E.L. Winstanley, A.M. O’Melia, N. Mori, J. McCoy, P.E. Keck Jr., J.J. Hudson, Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial, Int. J. Eat. Disord. 44 (2011) 81–90.

[52] C.S. Maldonado-Irizarry, C.J. Swanson, A.E. Kelley, Glutamate receptors in the nucleus accumbens shell control feeding behavior via the lateral hypothalamus, J. Neurosci. 15 (1995) 6779–6788.

[53] R. Matyukova, L. Maletinska, J. Maixnerova, Z. Pirnik, A. Kiss, B. Zelezna, Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice, Physiol. Res. 57 (2008) 727–734.

[54] G. Gadino-Cabrera, M.E. Urena-Guerro, M.C. Rivera-Cervantes, A.J. Feria-Velasco, C. Bear-Zarate, Excitotoxicity triggered by neonatal monosodium glutamate treatment and blood–brain barrier function, Arch. Med. Res. 45 (2014) 653–659.

[55] D.B. Guard, T.D. Swartz, R.C. Ritter, G.A. Burns, M. Covasa, NM2A NR2 receptors participate in CCK-induced reduction of food intake and hindbrain neuronal activation, Brain Res. 1266 (2009) 37–44.

[56] J.M. Reich, B. Maunze, K.A. Phillips, S. Choi, Inhibition of food intake by PACAP in the hypothalamic ventromedial nucleus is mediated by NM2A receptors, Physiol. Behav. 133 (2014) 230–235.

[57] S.L. McElroy, A.J. Guerdjikova, N. Mori, A.M. O’Melia, Pharmacological management of binge eating disorder: current and emerging treatment options, Ther. Clin. Risk Manag. 8 (2012) 219–241.